文献速递肝病

HBeAg阳性慢性乙型肝炎病毒感染干扰素α治疗的超长期随访

Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-09-03

该研究对1977—2014年间在一家三级转诊中心接受(聚乙二醇)干扰素α治疗的267例HBeAg阳性慢性乙型肝炎患者进行超长期随访,中位随访11.5年,5年和10年累积HBsAg清除率分别为14%和32%,HBeAg和HBsAg清除均与临床结局改善显著相关,早期HBeAg清除与更多HBsAg清除及更好结局相关。

要点

  • 267例HBeAg阳性慢乙肝患者接受(聚乙二醇)干扰素α治疗,中位随访11.5年。
  • 5年和10年累积HBsAg清除率分别为14%和32%。
  • HBeAg和HBsAg清除均与临床结局改善显著相关。

核心结论

  • 长期随访中,单疗程(聚乙二醇)干扰素α治疗观察到较高的HBsAg清除率。
  • 其持续效应提示干扰素α仍有一定作用,可能用于追求功能性治愈的新型联合治疗。

研究设计与样本

  • 研究纳入1977—2014年间在一家三级转诊中心接受(聚乙二醇)干扰素α治疗的HBeAg阳性患者。
  • 研究回顾病历并查询市政登记处获取患者信息,随访数据缺失者被邀请至门诊进行一次访视。
  • 研究队列共267例患者,67%为男性,58%为白人,中位年龄32岁,中位随访11.5年。

主要发现

  • 5年和10年累积HBsAg清除率分别为14%和32%。
  • 与HBsAg清除率较高相关的基线因素包括男性、白人种族、A基因型、年龄≥40岁和肝硬化。
  • 短期(≤24周)与长期(>24周)治疗者的HBsAg清除率无显著差异。
  • HBeAg和HBsAg清除均与临床结局改善显著相关。
  • 早期应答(HBeAg清除)与更多HBsAg清除和更好患者结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Interferon-alpha (IFN-α) treatment for chronic hepatitis B (CHB) virus infection is finite and leads to relatively higher functional cure rates (HBsAg loss) than nucleo(s)tide analogue (NA) therapy. Effects of pegylated (PEG)/conventional IFN-α treatment on clinical outcomes were evaluated in an ultra-long-term follow-up of CHB patients. METHODS: HBeAg-positive patients treated with (PEG)IFN-α at a tertiary referral centre between 1977-2014 were included. We reviewed medical charts and consulted the municipal registry for patient information. Patients were invited for a single visit at the outpatient clinic in the case of missing follow-up data. The endpoints included serum HBeAg/HBsAg loss and incidence of clinical events, using life table methods and person-years to analyze the incidence of events. Patients were censored upon retreatment. RESULTS: The study cohort included 267 patients, 67% male, 58% Caucasian, with a median age of 32 years. The median follow-up duration was 11.5 years. The 5 and 10-year cumulative incidence of HBsAg loss were 14% and 32%, respectively. Baseline factors associated with a higher rate of HBsAg loss were male sex, Caucasian race, genotype A, age ≥40 years, and cirrhosis. HBsAg loss rates did not differ significantly between those who received short-term (≤24 weeks) vs long-term (>24 weeks) therapy. Both HBeAg and HBsAg loss were significantly associated with improved clinical outcomes. Early response (HBeAg loss) was associated with more HBsAg loss and better patient outcomes. CONCLUSIONS: During long-term follow-up, high rates of HBsAg loss were observed from a single (PEG)IFN-α course. Its persistent effects suggest that a role for IFN-α remains, potentially in novel combination therapies in search of a functional cure.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Choi HSJ, van Campenhout MJH, van Vuuren AJ, et al. Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2020. PMID: 32890755. doi:10.1016/j.cgh.2020.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。